Key Market Indicator:
F&G: 47
25.280,50 NASDAQ · 48.250,00 DOW · 6.831,35 S&P · 4.316,87 Gold · 59,84 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© BusinessWire
04.12.2025
ISIN: US71944F1066

Phreesia, Inc.
PHR

LISTED

NYSE
Phreesia’s Megan Turco Named to MM+M 40 Under 40
News Preview
Phreesia today announced that Megan Turco, Director of Client Experience for Phreesia Network Solutions, has been named to MM+M’s 2025 40 Under 40 list. MM+M’s annual 40 Under 40 list celebrates standout talent across healthcare marketing and communications. This year’s honorees were chosen for their impact in shaping the future of medical market...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US45257U1088

Immunome Inc
IMNM

LISTED

NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US68218J1034

OmniAb Inc
OABI

LISTED

NASDAQ
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
News Preview
OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb’s newest technology offering, OmniUltra, the industry's only transgenic c...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
04.12.2025
ISIN: US64135M1053

Neurogene Inc
NGNE

LISTED

NASDAQ
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
04.12.2025
ISIN: US69608A1088

Palantir Technologies, Inc.
PLTR

LISTED

NASDAQ
Northslope Signs Large-Scale Expansion for Deployment of Palantir AI FDE and Demonstrates Accelerated Growth; Palantir Recognizes Northslope as the First Partner of the Vanguard: Elite
News Preview
Northslope, the first and fastest growing Palantir-native applied AI company, today announced a deepened strategic partnership with Palantir (NASDAQ: PLTR). This partnership also recognizes Northslope as the first member of the Palantir Vanguard: Elite network, reflecting Northslope’s expanding AI outcomes for customers on Palantir platforms. This...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US89680M1018

TriSalus Life Sciences, Inc.
TLSI

LISTED

NASDAQ
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring J...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US15713L1098

CervoMed Inc.
CRVO

LISTED

NASDAQ
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
News Preview
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US05356F1057

Aveanna Healthcare Holdings Inc
AVAH

LISTED

NASDAQ
Aveanna to Participate at the BofA Securities Home Care Conference
News Preview
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the BofA Securities Home Care Conference virtually on December 9, 2025. Management will present at 12:30pm EST and will also host 1x1 investor meetings that same day. Interested investors and...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US29384C1080

Entrada Therapeutics Inc
TRDA

LISTED

NASDAQ
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Entrada Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US2166484020

Cooper Companies Inc
COO

LISTED

NYSE
CooperCompanies Announces New Chair of the Board and Strategic Review
News Preview
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US2166484020

Cooper Companies Inc
COO

LISTED

NYSE
CooperCompanies Announces Fourth Quarter and Full Year 2025 Results
News Preview
SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US04300J1079

Protara Therapeutics, Inc.
TARA

LISTED

NASDAQ
Protara Announces Proposed Public Offering
News Preview
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu o...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.12.2025
ISIN: US74006W1080

Praxis Precision Medicines Inc
PRAX

LISTED

NASDAQ
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
News Preview
Successful interim analysis triggered early stop for efficacy...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US5588681057

Madrigal Pharmaceuticals Inc
MDGL

LISTED

NASDAQ
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
News Preview
CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 1, 2025 to 24 new non-executive employees as equity inducemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US74006W1080

Praxis Precision Medicines Inc
PRAX

LISTED

NASDAQ
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
News Preview
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US40637H1095

Halozyme Therapeutics Inc
HALO

LISTED

NASDAQ
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
News Preview
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany.The Munich Regional Court's 7th Civil Division found that there is imminent infringem...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: LU2458332611

Alvotech SA
ALVO

LISTED

ICE
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51

SCHOTT Pharma AG & Co KgaA
1SXP

LISTED

XETR
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose
News Preview
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose Vorläufige Ergebnisse für das Geschäftsjahr 2025 entsprechen der Prognose: Umsatz von 986,2 Mio. Euro (währungsbereinigtes Wachstum von 5,8 %) EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %) währungsberein......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51

SCHOTT Pharma AG & Co KgaA
1SXP

LISTED

XETR
Outlook for fiscal year 2026 and update of mid-term guidance
News Preview
SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as o......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51

SCHOTT Pharma AG & Co KgaA
1SXP

LISTED

XETR
Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose
News Preview
SCHOTT Pharma: Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose Für das Geschäftsjahr 2026 erwartet SCHOTT Pharma ein währungsbereinigtes Umsatzwachstum im Bereich von 2-5% sowie eine EBITDA-Marge von rund 27%. Diese Prognose weicht von den aktuellen Markterwartungen von 8,2% währungsbereinigtem Wachstum und einer......
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US0021202025

Atyr Pharma, Inc.
ATYR

LISTED

NASDAQ
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 8, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US9139031002

Universal Health Services Inc
UHS

LISTED

NYSE
UNIVERSAL HEALTH SERVICES INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Universal Health Services’s Directors and Officers for Breach of Fiduciary Duties – UHS
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Universal Health Services, Inc. (NYSE: UHS) breached their fiduciary duties to Universal Health and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members o...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US3741631036

Geron Corp
GERN

LISTED

NASDAQ
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
News Preview
Issued on behalf of GT Biopharma, Inc.USA News Group News CommentaryVANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US3741631036

Geron Corp
GERN

LISTED

NASDAQ
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
News Preview
Issued on behalf of GT Biopharma, Inc.USA News Group News CommentaryVANCOUVER, BC, Dec. 4, 2025 /CNW/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is reve...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US58933Y1055

Merck & Co Inc
MRK

LISTED

NYSE
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
News Preview
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest cla...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US0028241000

Abbott Laboratories
ABT

LISTED

NYSE
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
News Preview
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakesEnsure Max Protein 42g: For physically active adults, this new shake delivers 42 grams of complete protein to help bu...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US16359R1032

Chemed Corp
CHE

LISTED

NYSE
Chemed Corporation to Present at the BofA Securities 2025 Virtual Home Care Conference
News Preview
CINCINNATI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2025 Virtual Home Care Conference on Tuesday, December 9, 2025, at 1:20 PM (ET)....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: DK0060448595

Coloplast A/S
COLO B

LISTED

CPH
Coloplast A/S - Decisions at the Annual General Meeting 2025
News Preview
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: GB00BN455J50

Worldwide Healthcare Trust PLC
WWH

LISTED

LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.12.2025
ISIN: US69608A1088

Palantir Technologies, Inc.
PLTR

LISTED

NASDAQ
Cubic and Palantir Forge Alliance to Accelerate Transformation and Deliver Outcomes for the U.S. Army
News Preview
SAN DIEGO, CA AND DENVER, CO / ACCESS Newswire / December 4, 2025 / Cubic Corporation and its DTECH Mission Solutions business unit, a recognized industry leader in providing trusted, scalable, and intuitive edge compute and networking platforms, today announced a strategic relationship with Palantir Technologies Inc. (NASDAQ:PLTR), to drive large-...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US00404A1097

Acadia Healthcare Company Inc
ACHC

LISTED

NASDAQ
Securities Fraud Investigation Into Acadia Healthcare Company, Inc. (ACHC) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US4831191030

Kala Pharmaceuticals Inc
KALA

LISTED

NASDAQ
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2025
ISIN: CA4236943060

Hemostemix Inc.
HEM

LISTED

TSX
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
News Preview
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations....
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US9286611077

VolitionRX Ltd
VNRX

LISTED

XASE
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
News Preview
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for pr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US28176E1082

Edwards Lifesciences Corp.
EW

LISTED

NYSE
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
News Preview
Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), m...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US17322U3068

Citius Pharmaceuticals Inc
CTXR

LISTED

NASDAQ
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
News Preview
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAELYMPHIR international availability extends to 19 markets outside the U.S.CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: IL0011313900

Galmed Pharmaceuticals Ltd.
GLMD

LISTED

NASDAQ
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
News Preview
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July 2042.Aramchol is a first-in-class, Phase 3 ready, drug candidate, that showed robust fibrosis improvement in advanced clinical studies...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: BE0003739530

UCB SA
UCB

LISTED

EURONEXT
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
News Preview
Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including the presentation of positive primary efficacy and safety results from a phase 3 study of FINTEPLA® (fenfluramine)1 in CDD, marking the third developmental and epileptic encephalopathy (DEE) to see positive results following Dravet syndrome (DS) and Lenno...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US2274831047

Cross Country Healthcare Inc
CCRN

LISTED

NASDAQ
Cross Country Healthcare Merger Agreement with Aya Healthcare Terminated
News Preview
Cross Country Healthcare, Inc. (the “Company” and “Cross Country Healthcare”) (Nasdaq: CCRN) today announced the termination of its Agreement and Plan of Merger (the “Merger Agreement” and, the transactions contemplated thereby, the “Aya Merger”) with Aya Holdings II Inc., a Delaware corporation (“Parent”), Spark Merger Sub One Inc., a Delaware co...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US2521311074

Dexcom Inc
DXCM

LISTED

NASDAQ
Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
News Preview
DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Sa...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US1266501006

CVS Health Corp
CVS

LISTED

NYSE
Aetna expands initiatives to simplify experiences for health care professionals and patients
News Preview
Bundling medical procedures and pharmaceutical medications into one prior authorizationImplementing end-to-end generative AI capabilities into Aetna Health appHARTFORD, Conn., Dec. 4, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announces key milestones in support of the company's comprehensive strategy announced in June t...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US04962H2094

Atossa Therapeutics, Inc.
ATOS

LISTED

NASDAQ
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
News Preview
Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settingsSEATTLE, Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the comple...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US81063V2043

Odysight.ai Inc
ODYS

LISTED

NASDAQ
ODYSIGHT.AI ANNOUNCES SUCCESSFUL PROOF-OF-CONCEPT IN THE GLOBAL MINE TRUCK SEGMENT CONDUCTED WITH A MAJOR INTERNATIONAL AUTOMOTIVE OEM
News Preview
OMER, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leader in AI-powered visual sensing and Predictive Maintenance (PdM) solutions, announces the successful completion of a Proof of Concept (POC) project in the global mine truck segment conducted with a major international automotive OEM....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US09077V1008

BIOAGE Labs Inc
BIOA

LISTED

NASDAQ
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
News Preview
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US15119A2024

Celsus Therapeutics PLc
CLTX

LISTED

NASDAQ
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
News Preview
Access the Akari CEO Corner here...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2025
ISIN: US29415V1098

ENvue Medical, Inc.
FEED

LISTED

NASDAQ
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
News Preview
Event to Take Place December 11th at 4:30 P.M. ETWhite Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:3...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US29405E5050

Enveric Biosciences, Inc.
ENVB

LISTED

NASDAQ
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
News Preview
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 d...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US90184D1000

Twist Bioscience Corp
TWST

LISTED

NASDAQ
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
News Preview
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers’ pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and co...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US2975841048

Estrella Immunopharma, Inc.
ESLA

LISTED

NASDAQ
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
News Preview
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I do...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
ISIN: US0718131099

Baxter International, Inc.
BAX

LISTED

NYSE
Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
News Preview
Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amende...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US45828J1034

Intensity Therapeutics, Inc.
INTS

LISTED

NASDAQ
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
News Preview
SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and incr...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US2521311074

Dexcom Inc
DXCM

LISTED

NASDAQ
DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DXCM
News Preview
LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: CA23126M1023

Curaleaf Holdings Inc
CURA

LISTED

TSX
Curaleaf Expands Florida Footprint with New Cape Canaveral Dispensary
News Preview
New location along Florida's Space Coast brings store count to 70 statewide and 159 nationwideSTAMFORD, Conn., Dec. 4, 2025 /CNW/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the opening of its latest dispensary in Cape Canaveral...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: CA23126M1023

Curaleaf Holdings Inc
CURA

LISTED

TSX
Curaleaf Expands Florida Footprint with New Cape Canaveral Dispensary
News Preview
New location along Florida's Space Coast brings store count to 70 statewide and 159 nationwideSTAMFORD, Conn., Dec. 4, 2025 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the opening of its latest dispensary in Cape Ca...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: CA58504D1006

Medipharm Labs Corp
LABS

LISTED

TSX
MediPharm Labs Completes First Shipment to France
News Preview
MediPharm Labs is pleased to announce the completion of the Company's first shipment to France....
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US44975P1030

I-Mab
IMAB

LISTED

NASDAQ
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
News Preview
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-respo...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: US89532M1018

Trevi Therapeutics Inc
TRVI

LISTED

NASDAQ
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
News Preview
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growthNEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
ISIN: IL0011809592

NeuroSense Therapeutics Ltd.
NRSN

LISTED

NASDAQ
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
News Preview
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advanc...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US50172J1051

Exousia Bio, Inc.
LMMY

LISTED

OTC
Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
News Preview
OTC:LMMY Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US92536C1036

Veru Inc
VERU

LISTED

NASDAQ
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
News Preview
MIAMI, FL, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced multiple presentations at The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) 18th Internati...
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 17.12.2025, Calendar Week 51, 351st day of the year, 14 days remaining until EoY.